Author

Carol Iredale

Observed name: Iredale, Carol

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

OpenAlex ID: A5066865652

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes

2017 · Philip Home, R. Ravi Shankar, et al. · Diabetes Research and Clinical Practice · 16

A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy

2017 · Yehuda Handelsman, Brett Lauring, et al. · Current Medical Research and Opinion · 16

Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study

2019 · Juan P. Frias, Zachary Zimmer, et al. · Diabetes Obesity and Metabolism · 12

Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds

2017 · Ira Gantz, Liubov Sokolova, et al. · Clinical Therapeutics · 7

Works count: 5

Citation count: 51

H-index: 4

I10-index: 3